OVERVIEW

New Therapies for Lung Cancer is organized by The Ohio State University Center for Continuing Medical Education (OSUCCME).

Event Dates: 10/12/2018 - 10/12/2021

Accreditation:
AMA Credit Designation Statement
The Ohio State University Center for Continuing Medical Education (CCME) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Description:
Today on MedNet21, we're going to discuss New Therapies for Lung Cancer.

After this presentation, learners should appreciate the magnitude of the lung cancer problem, aware of the rapid pace of progress in this disease, and be better versed on some of the latest advances in the management of lung cancer.

Objective(s):
As a result of this educational activity, webcast participants will be able to: Review some of the latest practice-changing findings in the management of lung cancer; and Understand the basic principles of workup and initial lung cancer management decisions. You’ll also learn about the following:
• Classifying non-small cell lung cancer
• Common side effects of driver-targeted therapies
• What the primary care physician needs to know about co-managing patients taking driver-targeted therapy

Additional details will be posted as soon as information is available.